Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Stifel analysts adjusted their stance on Exelixis (NASDAQ:EXEL) shares, raising the price target to $36 from the previous $30, while keeping a Hold rating on the stock. The new price target reflects ...

JMP Securities maintained a Market Outperform rating and a $41.00 price target for Exelixis (NASDAQ:EXEL) shares, aligning with the broader analyst consensus as five analysts have recently revised ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...